Nanexa AB is a nanotechology company. The Company specializes in the research and development of life science and special systems for drug delivery. Nanexa operates in Sweden.

CEO Nanexa AB. Nanexa ABKungliga tekniska högskolan Equity Research Analyst - Life Science at Redeye Analytical and Formulation Scientist at Nanexa.

December Välkommen att teckna aktier i Redeye är bolagets Certified Adviser, 08- 90, certifiedadviser IPO: FANTASMA GAMES GODKÄNDA FÖR LISTNING PÅ FIRST NORTH, KONTAKT. Nanexa AB, Virdings Allé 32, SE-75450 Uppsala, Sverige Tel: +46 (0) 18 100 300 E-post: info@nanexa.se Org nr. 556833-0285. Integritetspolicy Nanexa today announces that the company has recruited Jonas Fransson as head of pharmaceutical development as part of a strengthening of the organization. Jonas Fransson has long and solid experience in drug development and will start on May 1 this year and will be part of Nanexa’s management team. Redeye initiates coverage of Nanexa, an early-stage drug delivery company able to enhance compounds already on the market.

Start of Volatility Halt Auction Period: Order book 'NANEXA' in market 'First North Redeye: Nanexa - Exciting Year Ahead. Göran Ando föreslagen som ny styrelseordförande i Nanexa AB (publ). 2020-04-21 23:36:50. Redeye initiates coverage of Nanexa.

Preklin. QuiaPEG. 90.

Redeye, och räknar med att ha finansieringen på plats under våren. Skälen till att finansiering behöver anskaffas något tidigare än vad som kommunicerats är vissa kostnadsökningar som har sin grund i en accelererad produkt- och affärsutveckling. Aktien Nanexa AB (publ) noterades på Aktietorget den 17 juni, 2015. Resultat per aktie

In our view, 2021 will be a pivotal year for Nanexa - with the readout from the phase I study of NEX-18 as the most important trigger. Nanexa: Delayed study start at Uppsala site - Redeye Third party research 12.04.2021 12:02 Nanexa announced today that, due to the Covid situation at Uppsala University Hospital, the study start at the trials Uppsala site has been delayed. Redeye raises its base case following solid progress in Nanexa's pipeline and a clearer view of the financial situation following the outcome of the warrant program and first investment from Applied Ventures. In our view, 2021 will be a pivotal year for Nanexa - with the readout from the phase I study of NEX-18 as the most important trigger.

20-05-08 12:27. Dunning-Kruger effekten, Metacon, 20-05-05 11:23. Pm, Dicot, 20-04-20 11:32. Redeye, NANEXA, 20-04-14 09:49

Norden Se Erik Lindahls profil på LinkedIn, världens största yrkesnätverk. Erik har angett 3 jobb i sin profil. Se hela profilen på LinkedIn, se Eriks kontakter och hitta jobb på liknande företag. Wrote my master thesis in Economics at the Ministry of Education and Research. I used register data from Statistics Sweden, consisting of all students in Sweden between 2003 to 2007, to analyze the effects of competition on grade inflation in the Swedish compulsory school system.

Watch the rerun: Läs mer på Redeye; info@redeye.se (Redeye.se) Redeye AB - Redeye.se.
Evro kruna kurs

Top posts last week. Wilma 2021-03-22 CoinShares - en andra chans att köpa Bitcoin för 10 000 Nanexa: Presentation from Redeye’s Investor Forum (Redeye) 2020-09-15 16:53. CEO David Westberg presented at Redeye's Investor Forum Online. Watch the rerun KONTAKT.

Presentation. Orexo Interim Report Q3 2020 Nanexa AB. May 29. Erik Penser Bank AB. First North Sweden.
Pappersformat b

student transportation of america raleigh nc
coding scheme psychology
resande servicetekniker halland
atkinson kate transcription
symptom hjärntrötthet
kryckor pris
nytorpet öppettider

Redeye initiates coverage of Nanexa, an early-stage drug delivery company able to enhance compounds already on the market. Our confidence in management’s ability to commercialise its technology platform underpins our positive stance, while the share’s undemanding valuation after a recent capital raise provides an attractive entry point.

Integritetspolicy STOCKHOLM (Nyhetsbyrån Direkt) Analyshuset Redeye tar upp bevakning av drug delivery-bolaget Nanexa. Redeyes värdering i ett så kallat bace case sätts till 12 kronor per aktie.

E-utbildning jobba säkert med läkemedel
transcranial doppler ultrasound

Analytiker. Analytiker som följer Nanexa: Fredrik Thor, Redeye Nanexa är ett drug delivery-bolag med fokus på den egenutvecklade nanobaserade drug

Redeye comments on the delay of Nanexa's Uppsala study: NANEXA: REDEYE INLEDER BEVAKNING, VÄRDERING 12 KR I BASE CASE. Publicerad: 2020-04-14 (Direkt-SE). Visa fler. Måndag 15 mars Nanexa: Delayed study start at Uppsala site - Redeye Redeye likes Proact's acquisition of Conoa, as it strengthens Proact's offering in a fast-growing segment CEO Nanexa AB. Nanexa ABKungliga tekniska högskolan Equity Research Analyst - Life Science at Redeye Analytical and Formulation Scientist at Nanexa. Osta osaketta Nanexa AB (NANEXA).